Department of Clinical Medicine, University of Bergen, Bergen, Norway.
Department of Economics and Business Economics, Business and Social Science, National Center for Register-Based Research, School of Business and Social Sciences, Aarhus University, Aarhus, Denmark.
Epilepsia. 2024 Jun;65(6):1698-1708. doi: 10.1111/epi.17969. Epub 2024 Mar 30.
This study was undertaken to characterize the use of higher doses of folic acid (≥1 mg daily) in relation to pregnancy in Denmark, Norway, and Sweden in women with epilepsy treated with antiseizure medication (ASM).
In this observational study, we used data from national medical birth, patient, and prescription registers in Denmark, Norway, and Sweden to retrospectively identify pregnancies in women with epilepsy treated with ASM from 2006 to 2017. The proportion of higher dose folic acid supplementation in pregnancies among women receiving ASM for epilepsy was calculated according to country of origin, time period, and type of ASM. Logistic regression with restricted cubic splines was used to model country-specific time trends.
Among a total of 2 748 882 pregnancies, we identified 8695 (.3%) pregnancies after restricting the population to women with ASM-treated epilepsy. A prescription for higher dose folic acid was filled in 4719 (54.3%) of these pregnancies. The proportion supplemented with higher dose folic acid was highest in Sweden (74.3%) and lower in Norway (41.4%) and Denmark (34.3%). Furthermore, we observed a decreasing trend of higher dose folic acid use in Denmark and Norway from year 2012 to 2017. Among those who used higher dose folic acid, 42% did not start preconception supplementation with higher dose folic acid.
Supplementation with higher dose folic acid occurred in approximately half of pregnancies in women with ASM-treated epilepsy, with many not starting supplementation until after becoming pregnant. Considerable variability was observed in the use of higher dose folic acid across the countries, despite similar population characteristics and health care systems. Future guidelines should be simplified with clear recommendations developed in a collaborative manner by relevant specialists including neurologists, obstetricians, pediatricians, and public health specialists to enhance real-world applicability.
本研究旨在描述丹麦、挪威和瑞典在使用抗癫痫药物(ASM)治疗的癫痫女性中,与妊娠相关的较高剂量叶酸(≥1mg/天)的使用情况。
在这项观察性研究中,我们使用丹麦、挪威和瑞典的国家医疗出生、患者和处方登记处的数据,回顾性地确定了 2006 年至 2017 年期间接受 ASM 治疗的癫痫女性的妊娠情况。根据原籍国、时间段和 ASM 类型,计算了接受 ASM 治疗的癫痫女性妊娠中较高剂量叶酸补充的比例。采用受限三次样条的逻辑回归模型来拟合国家特定的时间趋势。
在总共 2748882 例妊娠中,我们在限制人群为接受 ASM 治疗的癫痫女性后,确定了 8695 例(0.3%)妊娠。在这些妊娠中,有 4719 例(54.3%)开具了较高剂量叶酸的处方。在瑞典(74.3%),挪威(41.4%)和丹麦(34.3%),补充较高剂量叶酸的比例最高。此外,我们观察到丹麦和挪威从 2012 年到 2017 年,较高剂量叶酸使用呈下降趋势。在使用较高剂量叶酸的人群中,有 42%的人没有在受孕前开始补充较高剂量叶酸。
在接受 ASM 治疗的癫痫女性中,约有一半的妊娠中补充了较高剂量的叶酸,但许多人直到怀孕后才开始补充。尽管各国的人口特征和医疗保健系统相似,但仍观察到较高剂量叶酸的使用存在相当大的差异。未来的指南应该简化,由包括神经病学家、妇产科医生、儿科医生和公共卫生专家在内的相关专家以协作的方式制定明确的建议,以增强现实适用性。